US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,394.28

-9.7291-0.69%

Number of Gainers:1

Number of Losers:9

Number of Flat:2

PE:- -

High:1,409.65

Open:1,403.41

Low:1,384.46

Close:1,403.94

Loading ...

Gilead reports ASCENT-04/KEYNOTE-D19 study met primary endpoint

Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer

Viatris price target lowered to $8 from $10 at BofA

Applied DNA’s LineaRx ‘ready to support’ reshoring of drug development

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Viatris Applies for Japan Approval of Effexor to Treat Generalized Anxiety Disorder

MT Newswires Live

Gilead: Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study

THOMSON REUTERS

Gilead: Overall Survival (Os), Key Secondary Endpoint, Wasn't Mature at Time of Pfs Primary Analysis

THOMSON REUTERS

Gilead: Study Met Main Goal, With Statistically Significant,Clinically Meaningful Improvement in Pfs

THOMSON REUTERS

Gilead: Will Continue to Monitor Os Outcomes

THOMSON REUTERS

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated Pd-L1+ Metastatic Triple-Negative Breast Cancer

THOMSON REUTERS

Bet on These 5 Top-Ranked Stocks With Rising P/E

BRIEF-Viatris Files Supplemental New Drug Applications To Japan's Ministry Of Health, Labor And Welfare For The Approval Of Effexor®

Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of Effexor® for the Treatment of Generalized Anxiety Disorder

THOMSON REUTERS

Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell

MT Newswires Live

Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?

BRIEF-Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479

Nurix Therapeutics Inc - to Receive $5 Million Milestone Payment From Gilead

THOMSON REUTERS

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

Siga Technologies Inc. (SIGA) Stock Moves -1.82%: What You Should Know

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1394.2075,"timestamp":1745263676198,"preClose":1403.9366,"halted":0,"volume":14411837,"delay":0,"changeRate":-0.00693,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-9.729126,"latestTime":"04-21 15:27:56 EDT","open":1403.4071,"high":1409.6544,"low":1384.4579,"amount":677357831.762009,"amplitude":0.017947,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745265600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.482004,"peRate":759.167081,"turnoverRate":0.005304,"increases":1,"decrements":9,"flats":1,"marketCap":157307256759.25,"floatMarketCap":156683983635.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1409.6544,"amplitude":0.017947,"preClose":1403.9366,"low":1384.4579,"pbRate":"3.482004","latestPrice":1394.2808,"volume":14413740,"delay":0,"open":1403.4071,"prevYearClose":1284.7982,"prevWeekClose":1403.9366,"prevMonthClose":1502.9401,"prevQuarterClose":1502.9401,"fiveDayClose":1393.7178,"twentyDayClose":1452.8525,"sixtyDayClose":1279.2769,"secType":"PLATE","market":"US","turnoverRate":0.005304,"peRate":759.167081,"marketCap":157307256759.25,"floatMarketCap":156683983635.75,"timestamp":1745263681641,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":1,"down":9,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529800286","title":"Gilead reports ASCENT-04/KEYNOTE-D19 study met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2529800286","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529800286?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:15","pubTimestamp":1745244937,"startTime":"0","endTime":"0","summary":"Gilead Sciences (GILD) announced topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda significan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-reports-ascent-04-keynote-d19-study-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-reports-ascent-04-keynote-d19-study-met-primary-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0266013472.USD","LU0965509101.SGD","LU1917777945.USD","LU1035773651.USD","GILD","LU1116320901.HKD","LU0265550359.USD","BK4534","SG9999001176.USD","SG9999002232.USD","LU1941712348.USD","SG9999002224.SGD","LU0965509283.SGD","LU1983299246.USD","SG9999014575.USD","LU1023059063.AUD","LU1571399168.USD","BK4516","IE0002141913.USD","LU1116320737.USD","LU1585245621.USD","LU1989772840.SGD","LU1061106388.HKD","LU1093756325.SGD","SG9999001440.SGD","BK4568","LU0006306889.USD","BK4583","IE00B1BXHZ80.USD","LU0234572021.USD","LU1066051811.HKD","IE00BLSP4239.USD","LU0058720904.USD","LU2112291526.USD","LU1066051225.USD","IE00B2B36J28.USD","LU1430594728.SGD","LU2468319806.SGD","LU0109394709.USD","LU1934455277.USD","LU1941712264.USD","BK4585","BK4550","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","MRK","LU0861579265.USD","LU0289739699.SGD","LU2361044865.SGD","BK4578"],"gpt_icon":0},{"id":"2529800281","title":"Gilead ASCENT-04 data a ‘welcome surprise,’ says Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529800281","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529800281?lang=en_us&edition=fundamental","pubTime":"2025-04-21 22:15","pubTimestamp":1745244927,"startTime":"0","endTime":"0","summary":"Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not expecting t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-ascent-04-data-a-welcome-surprise-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-ascent-04-data-a-welcome-surprise-says-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","GILD","BK4568","LU1066053197.SGD","LU1585245621.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1571399168.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","BK4139","IE00B3T34201.USD","LU0109394709.USD","BK4583","LU1066051498.USD","OPY","LU2087621335.USD","BK4532","BK4550","IE0002270589.USD","BK4588","LU0289739699.SGD","BK4566","BK4578","LU2089984988.USD","BK4585","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","BK4127","LU1839511570.USD"],"gpt_icon":0},{"id":"2529807556","title":"Viatris price target lowered to $8 from $10 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807556","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807556?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:41","pubTimestamp":1745242890,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Viatris (VTRS) to $8 from $10 and keeps an Underperform rating on the shares. The firm, in its preview of Q...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viatris-price-target-lowered-to-8-from-10-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viatris-price-target-lowered-to-8-from-10-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VTRS","BK4583","LU2087621335.USD","BK4007","LU1839511570.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2529080146","title":"Applied DNA’s LineaRx ‘ready to support’ reshoring of drug development","url":"https://stock-news.laohu8.com/highlight/detail?id=2529080146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529080146?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:11","pubTimestamp":1745241086,"startTime":"0","endTime":"0","summary":"Applied DNA Sciences (APDN) has completed a long-term initiative to source critical input materials for its LineaDNA and LineaIVT platforms from U....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/applied-dnas-linearx-ready-to-support-reshoring-of-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/applied-dnas-linearx-ready-to-support-reshoring-of-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4109","BK4139","BK4544","BK4583","BK4585","BK4588","APDN","DNA","ARKG"],"gpt_icon":0},{"id":"2529000618","title":"Why Investors Need to Take Advantage of These 2 Medical Stocks Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2529000618","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529000618?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:00","pubTimestamp":1745240408,"startTime":"0","endTime":"0","summary":"Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to look at a qualifying stock. CVS Health  holds a Zacks Rank #3 at the moment and its Most Accurate Estimate comes in at $1.68 a share 10 days away from its upcoming earnings release on May 1, 2025.CVS is one of just a large database of Medical stocks with positive ESPs. Another solid-looking stock is Gilead Sciences .This article originally publishe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-investors-advantage-2-medical-130008567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU0061475181.USD","BK4581","GILD","LU0072461881.USD","BK4568","LU1066053197.SGD","LU0162691827.USD","LU1585245621.USD","ISBC","IE00B19Z3581.USD","LU0211331839.USD","LU2468319806.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1571399168.USD","LU1699723380.USD","IE00B19Z3B42.SGD","BK4196","LU0320765992.SGD","BK4504","BK4139","IE00B3T34201.USD","LU0109394709.USD","BK4583","LU0006061336.USD","LU0070302665.USD","LU1066051498.USD","BK4211","LU2087621335.USD","BK4532","CVS","BK4550","LU0208291251.USD","IE0002270589.USD","LU1059921491.USD","BK4588","LU0289739699.SGD","BK4566","LU0320765489.SGD","BK4578","LU2089984988.USD","BK4585","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","LU1839511570.USD"],"gpt_icon":0},{"id":"2529057308","title":"Viatris Applies for Japan Approval of Effexor to Treat Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2529057308","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529057308?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:34","pubTimestamp":1745238865,"startTime":"0","endTime":"0","summary":"Viatris  said Monday that it filed supplemental new drug applications to Japan's Ministry of Health, Labor and Welfare for approval of Effexor SR Capsules to treat adults with generalized anxiety disorder.The application follows a phase 3 randomized, double-blind study in Japan which met its primary objective of superiority over a placebo at eight weeks as well as seven secondary efficacy endpoints, the company said.Effexor is currently approved in Japan to treat major depressive disorder in adults, Viatris said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VTRS","BK4583","BK4585","BK4007","LU2087621335.USD","LU1839511570.USD","BK4588"],"gpt_icon":0},{"id":"2529805192","title":"Gilead: Positive Topline Results From Phase 3 Ascent-04/Keynote-D19 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2529805192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529805192?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4585","LU0889565916.HKD","LU1839511570.USD","LU0320765992.SGD","GILD","LU0109394709.USD","BK4568","IE00B3T34201.USD","LU1430594728.SGD","LU1571399168.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0234570918.USD","BK4532","IE00BKVL7J92.USD","LU1066053197.SGD","LU2468319806.SGD","BK4578","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE00B19Z3581.USD","BK4550","LU2087621335.USD","LU2089984988.USD","BK4588","BK4139","LU1066051498.USD","LU1585245621.USD","BK4566"],"gpt_icon":0},{"id":"2529805167","title":"Gilead: Overall Survival (Os), Key Secondary Endpoint, Wasn't Mature at Time of Pfs Primary Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2529805167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529805167?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GILD","LU2089984988.USD","BK4568","BK4139","LU1571399168.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU0058720904.USD","LU1839511570.USD","LU0109394709.USD","LU2087621335.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","LU1430594728.SGD","BK4588","BK4585","IE0002270589.USD","LU0320765992.SGD","LU0234570918.USD","IE00B3T34201.USD","LU1066053197.SGD","LU1585245621.USD","LU1066051498.USD","BK4583","BK4532","BK4550","BK4578"],"gpt_icon":0},{"id":"2529137805","title":"Gilead: Study Met Main Goal, With Statistically Significant,Clinically Meaningful Improvement in Pfs","url":"https://stock-news.laohu8.com/highlight/detail?id=2529137805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529137805?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GILD","IE00B3T34201.USD","IE00B7SZLL34.SGD","LU1571399168.USD","LU1839511570.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU2089984988.USD","LU2468319806.SGD","LU0058720904.USD","BK4583","IE00BSNM7G36.USD","LU0289739699.SGD","BK4550","BK4139","IE00B19Z3B42.SGD","BK4585","BK4566","LU1066051498.USD","BK4578","IE00BKVL7J92.USD","LU0234570918.USD","BK4532","LU2087621335.USD","LU0889565916.HKD","LU1430594728.SGD","LU0109394709.USD","LU1585245621.USD","LU1066053197.SGD","BK4568","IE00B19Z3581.USD","IE0002270589.USD","BK4588"],"gpt_icon":0},{"id":"2529051968","title":"Gilead: Will Continue to Monitor Os Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2529051968","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529051968?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nP8N3K10U9:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z3581.USD","LU1571399168.USD","IE00BKVL7J92.USD","BK4585","LU1430594728.SGD","BK4568","LU0058720904.USD","BK4550","IE00B19Z3B42.SGD","LU1066053197.SGD","GILD","LU1066051498.USD","IE00BSNM7G36.USD","BK4532","LU0234570918.USD","LU1839511570.USD","IE00B3T34201.USD","BK4583","BK4566","LU2087621335.USD","LU1585245621.USD","IE0002270589.USD","LU0109394709.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4139","LU2089984988.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4578","LU0889565916.HKD","BK4588"],"gpt_icon":0},{"id":"2529805156","title":"Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated Pd-L1+ Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529805156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529805156?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUACB5ZQM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","LU1585245621.USD","LU0889565916.HKD","LU0058720904.USD","BK4588","LU2087621335.USD","BK4532","BK4568","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","LU0234570918.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU0109394709.USD","IE00BZ1G4Q59.USD","GILD","LU2089984988.USD","LU1571399168.USD","BK4585","LU1066053197.SGD","IE00B3T34201.USD","BK4566","IE0002270589.USD","LU1839511570.USD","IE00BKVL7J92.USD","BK4578","IE00B7SZLL34.SGD","BK4550","LU2468319806.SGD","LU0320765992.SGD","BK4139","BK4583","LU1066051498.USD"],"gpt_icon":0},{"id":"2529202801","title":"Bet on These 5 Top-Ranked Stocks With Rising P/E","url":"https://stock-news.laohu8.com/highlight/detail?id=2529202801","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529202801?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:40","pubTimestamp":1745235600,"startTime":"0","endTime":"0","summary":"Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward — when a stock's current market price does not adequately reflect its higher earnings, it suggests potential for growth.But there is more to this whole P/E story. Because not only low P/E, stocks with a rising P/E can also fetch strong returns. In this regard, investors can bet on the likes of Carvana CVNA, Context Therapeutics Inc. CNTX, Inovio Pharmaceuticals INO, ChargePoint CHPT and MSA Safety Incorporporated MSA.The concept isthat as earnings rise, so should the price of the stock. As forecasts for expected earnings come in higher, strong demand for the stock should continue to push up its prices. After all, a stock's P/E gives an indication of how much investors are ready to shell out per dollar of earnings.Percentage price cha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bet-5-top-ranked-stocks-114000310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4143","CVNA","SPXU","BK4583","SPY","BK4007","BK4542","BK4551","VOO","BK4096","BK4139","ESmain","BK4214","OEF","CHPT","CNTX","IVV","BK4585","SSO","INO","BK4588","SDS","MSA","BK4534","LU1815336091.USD","BK4503",".SPX","BK4548","LU0053671581.USD","BK4581","LU1923622291.USD","LU0757428866.USD","OEX","SH","BK4568","LU0728928796.USD","LU2125909759.SGD","LU2211815571.USD","BK4550","BK4559","LU2125909916.SGD"],"gpt_icon":1},{"id":"2529874199","title":"BRIEF-Viatris Files Supplemental New Drug Applications To Japan's Ministry Of Health, Labor And Welfare For The Approval Of Effexor®","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874199","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874199?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:01","pubTimestamp":1745233314,"startTime":"0","endTime":"0","summary":"BRIEF-Viatris Files Supplemental New Drug Applications To Japan's Ministry Of Health, Labor And Welfare For The Approval Of Effexor April 21 (Reuters) - Viatris Inc VTRS.O:VIATRIS FILES SUPPLEMENTAL N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA7GDGFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","BK4588","BK4585","LU1839511570.USD","BK4583","BK4007","VTRS"],"gpt_icon":0},{"id":"2529874862","title":"Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of Effexor® for the Treatment of Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874862?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:59","pubTimestamp":1745233142,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA7GDGFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2087621335.USD","VTRS","BK4588","BK4583","BK4007","BK4585","LU1839511570.USD"],"gpt_icon":0},{"id":"2528711090","title":"Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2528711090","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528711090?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:33","pubTimestamp":1744893215,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics  said Thursday that the US Food and Drug Administration has cleared an investigational new drug application for its oral IRAK4 degrader GS-6791/NX-0479, allowing for a phase 1 trial to start, which is expected to begin in Q2.The company said it is to receive $5 million from Gilead Sciences  for the IND clearance and remains eligible for up to $420 million in potential future milestone payments as part of a 2019 collaboration agreement.Nurix said GS-6791/NX-0479 has potential applications in rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis.Under the terms of the 2019 collaboration agreement, Nurix and Gilead Sciences  are looking to discover, develop, and commercialize a pipeline of up to five therapies for cancer and other diseases, the company said.Nurix shares were over 8% higher while Gilead shares were 0.2% higher in recent premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2087621335.USD","IE00B7SZLL34.SGD","LU0058720904.USD","LU2089984988.USD","BK4139","IE00B19Z3B42.SGD","BK4550","BK4588","43A.SI","IE00BZ1G4Q59.USD","BK4578","GILD","LU0320765992.SGD","LU1585245621.USD","BK4585","BK4568","BK4583","LU0234570918.USD","LU1066053197.SGD","LU1430594728.SGD","LU1066051498.USD","IE00BKVL7J92.USD","LU0109394709.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","LU1839511570.USD","NRIX","BK6520","BK4532","BK4566","BK6054","LU0289739699.SGD","LU1571399168.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0889565916.HKD","IE0002270589.USD"],"gpt_icon":0},{"id":"2528771768","title":"Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2528771768","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528771768?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:49","pubTimestamp":1744890540,"startTime":"0","endTime":"0","summary":"While JAZZ Pharmaceuticals JAZZ may not be a typical cannabis stock, it is the only company to market an FDA-approved drug that contains a purified drug substance derived from marijuana.The company entered the medical cannabis space after acquiring GW Pharmaceuticals in 2021, adding two cannabidiol  drugs—Epidiolex and Sativex—to its portfolio. As the market for medical cannabis evolves and regulatory clarity improves, Jazz's early entry and growing footprint in this niche will position it as a serious contender for long-term gains.Let’s delve into the company’s strengths and weaknesses to better understand whether the stock deserves a place in your portfolio in 2025.Epidiolex Is on Fire—And So Is Jazz’s Growth Potential. Jazz’s involvement in the cannabis sector centers on Epidiolex—an oral solution approved for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. The drug was originally developed by GW Pharmaceuticals, a pioneer i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-top-cannabis-investment-114900445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CBD","BK4583","BK4510","BK4085","LU0889565916.HKD","LU0109394709.USD","IE00BN0W2T93.GBP","TLRY","BK4532","BK4563","IE00BN0W2W23.USD","BK4533","BK4596","IE00BN0W2V16.EUR","BK4113","JAZZ","LU0823416689.USD","CMRX","BK4139","BK4007","LU0320765992.SGD","BK4557","BK4547","IH"],"gpt_icon":1},{"id":"2528790993","title":"BRIEF-Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479","url":"https://stock-news.laohu8.com/highlight/detail?id=2528790993","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528790993?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:04","pubTimestamp":1744887869,"startTime":"0","endTime":"0","summary":"BRIEF-Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479 April 17 (Reuters) - Nurix Therapeutics Inc NRIX.O:NURIX ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR GS-6791/NX-0479 - A N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA7XL3YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","NRIX","LU1571399168.USD","LU1066051498.USD","LU2468319806.SGD","BK4566","LU1585245621.USD","BK4532","GILD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4550","IE00B19Z3581.USD","BK4585","BK4583","BK4139","BK4588","IE00BKVL7J92.USD","BK4578","LU0234570918.USD","BK4568","LU2089984988.USD","LU2087621335.USD","LU0109394709.USD","IE00B3T34201.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU1839511570.USD","LU1430594728.SGD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2528797017","title":"Nurix Therapeutics Inc - to Receive $5 Million Milestone Payment From Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797017","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797017?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:00","pubTimestamp":1744887601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA7XL3YT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066051498.USD","BK4532","IE00BKVL7J92.USD","LU1839511570.USD","LU1430594728.SGD","BK4585","LU1585245621.USD","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","NRIX","BK4139","BK4588","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU2087621335.USD","BK4550","BK4578","IE0002270589.USD","LU0320765992.SGD","LU1066053197.SGD","BK4566","LU1571399168.USD","LU0234570918.USD","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","BK4583","GILD","LU0889565916.HKD","IE00B3T34201.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2528578599","title":"Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2528578599","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528578599?lang=en_us&edition=fundamental","pubTime":"2025-04-17 06:00","pubTimestamp":1744840815,"startTime":"0","endTime":"0","summary":"The most recent trading session ended with Gilead Sciences  standing at $104.90, reflecting a -0.74% shift from the previouse trading day's closing. This change was narrower than the S&P 500's daily loss of 2.24%. Meanwhile, the Dow experienced a drop of 1.73%, and the technology-dominated Nasdaq saw a decrease of 3.07%.Shares of the HIV and hepatitis C drugmaker have depreciated by 4.13% over the course of the past month, outperforming the Medical sector's loss of 7.47% and the S&P 500's loss of 4.17%.Market participants will be closely following the financial results of Gilead Sciences in its upcoming release. The company plans to announce its earnings on April 24, 2025. In that report, analysts expect Gilead Sciences to post earnings of $1.73 per share. This would mark year-over-year growth of 231.06%. At the same time, our most recent consensus estimate is projecting a revenue of $6.83 billion, reflecting a 2.18% rise from the equivalent quarter last year.The Zacks Industry Rank ga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-stock-moves-220015275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0234570918.USD","BK4139","IE00BSNM7G36.USD","LU0289739699.SGD","BK4568","LU1839511570.USD","LU1585245621.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4588","IE00B19Z3581.USD","LU0058720904.USD","IE00B7SZLL34.SGD","BK4550","IE00B3T34201.USD","BK4585","BK4566","LU0889565916.HKD","BK4532","BK4578","GILD","BK4583","LU1066051498.USD","LU0109394709.USD","LU1066053197.SGD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU2087621335.USD","LU1571399168.USD","LU2468319806.SGD","IE00BKVL7J92.USD","LU0320765992.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2528320000","title":"Siga Technologies Inc. (SIGA) Stock Moves -1.82%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2528320000","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528320000?lang=en_us&edition=fundamental","pubTime":"2025-04-17 05:45","pubTimestamp":1744839916,"startTime":"0","endTime":"0","summary":"Siga Technologies Inc.  closed at $5.93 in the latest trading session, marking a -1.82% move from the prior day. This change was narrower than the S&P 500's 2.24% loss on the day. Elsewhere, the Dow saw a downswing of 1.73%, while the tech-heavy Nasdaq depreciated by 3.07%.Heading into today, shares of the company had gained 4.86% over the past month, outpacing the Medical sector's loss of 7.47% and the S&P 500's loss of 4.17% in that time.The investment community will be closely monitoring the performance of Siga Technologies Inc. in its forthcoming earnings report.Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Siga Technologies Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.In terms of valuation, Siga Technologies Inc. is presently being traded","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/siga-technologies-inc-siga-stock-214516501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4583","SIGA"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":83,"code":"91000000","status":"200"}]}}